Overweight and obesity and type 2 diabetes research hub

Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity and type 2 diabetes

This study is testing a new weekly injection combining two medicines, cagrilintide and semaglutide (called CagriSema), for people with type 2 diabetes who are also overweight or obese. It aims to see how well it helps with weight loss and managing blood sugar.